Biotechs & Pharmas Bracing For ASCO Annual Meeting
by Jon C. Ogg
24/7 Wall St.
This weekend we have the mother of all future cancer treatment conferences: ASCO, or The American Society of Clinical Oncology. Cancer stocks in the last few weeks have been seeing a muted response ahead of the event that biotech investors have traditionally braced for. At various points on the website you can find a full list of contributing and presenting companies. This is only a sample of the companies presenting data and it is very possible that the dates and even the companies may have changed. Also, you’ll probably start seeing news here at this ASCO News Site either late Thursday evening or Friday. Some of these dates and presentation schedules have been compiled over a multi-week period, so it is very likely that some of these will have changed.
SATURDAY, JUNE 2
Genentech (DNA) will show data with Roche on Avastin plus a chemotherapy dual-mix cocktail for first line treatment in non-small cell lung cancer patients. Later on at ASCO, a failed Avastin study for the treatment of pancreatic cancer will be shown. Some Phase III Avastin data in kidney cancer will also be presented next week. Genentech will also be showing data with partners OSI Pharmaceuticals (OSIP) and Imclone (IMCL) in later days.
Pfizer (PFE) will present data on Sutent’s safety and efficacy in Phase II liver cancer studies.
If you forgot about Dendreon (DNDN), this will be the company’s last known data presentation on Provenge after getting the FDA delay. Investors will be looking closely at any ‘New Data’ presented because much of the ongoing study data is being treated as old data.
Arqule (ARQL) and Exelixis (EXEL) are presenting data as well on molecules that are deemed cancer targets.
Continue article at 247WallSt.com
RELATED READING:
- Dendreon Volume and Volatility Compress Ahead of ASCO
- Cancer Stocks on the Go: It’s ASCO
- BioWatch Alert: ArQule Could See 15% Gain Ahead of ASCO
- Is Early Release of Study Data to Doctors Unfair?
______________________
24/7 Wall St.
This weekend we have the mother of all future cancer treatment conferences: ASCO, or The American Society of Clinical Oncology. Cancer stocks in the last few weeks have been seeing a muted response ahead of the event that biotech investors have traditionally braced for. At various points on the website you can find a full list of contributing and presenting companies. This is only a sample of the companies presenting data and it is very possible that the dates and even the companies may have changed. Also, you’ll probably start seeing news here at this ASCO News Site either late Thursday evening or Friday. Some of these dates and presentation schedules have been compiled over a multi-week period, so it is very likely that some of these will have changed.
SATURDAY, JUNE 2
Genentech (DNA) will show data with Roche on Avastin plus a chemotherapy dual-mix cocktail for first line treatment in non-small cell lung cancer patients. Later on at ASCO, a failed Avastin study for the treatment of pancreatic cancer will be shown. Some Phase III Avastin data in kidney cancer will also be presented next week. Genentech will also be showing data with partners OSI Pharmaceuticals (OSIP) and Imclone (IMCL) in later days.
Pfizer (PFE) will present data on Sutent’s safety and efficacy in Phase II liver cancer studies.
If you forgot about Dendreon (DNDN), this will be the company’s last known data presentation on Provenge after getting the FDA delay. Investors will be looking closely at any ‘New Data’ presented because much of the ongoing study data is being treated as old data.
Arqule (ARQL) and Exelixis (EXEL) are presenting data as well on molecules that are deemed cancer targets.
Continue article at 247WallSt.com
RELATED READING:
- Dendreon Volume and Volatility Compress Ahead of ASCO
- Cancer Stocks on the Go: It’s ASCO
- BioWatch Alert: ArQule Could See 15% Gain Ahead of ASCO
- Is Early Release of Study Data to Doctors Unfair?
______________________
posted by Nico at
7:15 AM
0 Comments:
Post a Comment
Subscribe to Post Comments [Atom]
<< Home